Immunex - Ad Hoc: Erfolgreiche Phase II Studie - 500 Beiträge pro Seite

[tom006]

Na, jetzt geht´s aber los. Ihr dürft mal raten, warum diese ad-hoc gerade kurz vor Bekanntgabe der Quartalsergebnisse rausgekommen ist.

Super news.

Tom

Abgenix and Immunex to Initiate Phase 2 Clinical Trial Of ABX-EGF in Kidney Cancer
WEDNESDAY, APRIL 18, 2001 9:00 AM
- PRNewswire

FREMONT, Calif. and SEATTLE, Apr 18, 2001 /PRNewswire via COMTEX/ -- Abgenix, Inc. (Nasdaq:ABGX) and Immunex Corporation (Nasdaq:IMNX) announced today that the companies will start a Phase 2 clinical trial of ABX-EGF in patients with kidney cancer. The Phase 2 trial will assess the tolerability and efficacy of ABX-EGF as monotherapy (without concomitant chemotherapy) in patients with kidney cancer. ABX-EGF is being developed jointly by Abgenix and Immunex. Initiation of this study triggers a milestone payment from Immunex to Abgenix.

This multi-center, multiple-dose study will enroll up to 80 patients across North America. Patients will receive eight weekly intravenous infusions at varying doses of ABX-EGF. Preliminary results from an ongoing Phase 1 study support the dose-escalating Phase 2 study protocol in kidney cancer.

"We are happy to be moving forward with the first of several Phase 2 trials for ABX-EGF, our lead oncology antibody therapy in development," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "In the coming months, Abgenix and Immunex will initiate a series of Phase 2 clinical trials to explore the tolerability and efficacy of ABX-EGF in additional cancer indications. Our hope is to provide effective, antibody-based therapeutic options for cancer patients."

"We are encouraged by the preliminary results we are seeing in the Phase 1 trial for ABX-EGF," said Douglas Williams, Ph.D., Immunex executive vice president and chief technology officer. "The potential ability of ABX-EGF to target the EGF receptor is an exciting approach in cancer research, making it a valuable addition to the Immunex arsenal of oncology molecules."

Preliminary results of an ongoing Phase 1 clinical trial of ABX-EGF will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in May 2001.

About ABX-EGF

ABX-EGF is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr), which is over-expressed on a variety of cancers including lung, breast, bladder, prostate, colorectal, kidney and head and neck cancer. It has been demonstrated that cancer cells can become dependent on growth signals mediated through the EGFr for their survival. In mouse models, ABX-EGF monotherapy has been shown to both eradicate established human tumors and block the growth of human tumors.

Overexpression of the EGFr has been reported to occur in 70-90% of kidney cancer tumors. In 2000, there were approximately 12,000 deaths associated with kidney cancer and approximately 31,000 new cases of kidney cancer in the United States. Renal cell carcinoma or kidney cancer is characterized by a lack of early warning signs, which results in a high proportion of patients being diagnosed with advanced disease. In cases where localized kidney tumors are detected at an early stage, surgery provides the only curative therapy. Metastatic kidney cancer is highly resistant to systemic therapies. Therapeutic options for patients with advanced kidney cancer are very limited.

"There is an unmet medical need for new treatment options for patients with kidney cancer," said Robert Figlin, M.D., Professor of Medicine and Urology of the Johnsson Comprehensive Cancer Center at the UCLA School of Medicine. "ABX-EGF, as a fully human monoclonal antibody, represents a promising therapeutic approach to solid tumors, and I am encouraged by its potential application in kidney cancer."

Abgenix is a biopharmaceutical company focused on the development and commercialization of fully human monoclonal antibody therapies for a variety of diseases. The company`s antibody technology platform, which includes XenoMouse(TM) technology, enables the rapid generation and selection of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix leverages its leadership position in human antibody technology by building a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products. For more information on Abgenix, visit the company`s website at www.abgenix.com.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.


SOURCE Immunex Corporation

[Shilka]

Interessiert jetzt keinen mehr diese Aktie, oder was ?????

[manuba]

scheint so!
alles, was nicht an einem tag um 10 oder mehr prozent steigt, wird links liegen gelassen. mir ist eine solche aktie alle mal lieber. immunex läßt einen, wenn auch langsamen, anstieg erkennen, der sich zweifelsohne fortsetzen wird. die produktionsengpässe wird man auch in den Griff bekommen, davon bin ich überzeugt. zumal immunex kein leichtgewicht an der börse ist, werden wir noch die eine oder andere überraschung erleben.

[puhvogel]

@tom006: Hol Sir mal ein Englisch-Deutsches Wörterbuch und übersetzt mal das Wort "initiate" aus der englischen Überschrift.
Dann vergleich die Übersetzung mit Deiner deutschen Überschrift.
Fällt was auf?
Gruss vom Sysyphos

[thebull 2]

Monday July 16, 4:55 pm Eastern Time

Immunex asks FDA to OK Enbrel for psoriatic arthritis

SEATTLE, July 16 (Reuters) - Immunex Corp. (NasdaqNM:IMNX - news) said on Monday it has filed an application with the
U.S. Food and Drug Administration for approval of Enbrel to treat psoriatic arthritis, a disease for which there are no approved
therapies.

The company said it had requested ``priority review`` status for its supplemental application for Enbrel, currently a treatment for rheumatoid arthritis.

If that priority review status is granted, the FDA would have to act on the supplemental application for Enbrel within six months, the company said.

Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, a chronic disease of the skin and nails, that affects an estimated 300,000 in the United
States.

gruss
tb 2